Peripheral artery disease (PAD) impacts 8.5 million Americans age 40 years or older, often leading to acute limb ischemia, amputation, hospitalization, revascularization, major adverse cardiac events (MACE), and death. In addition to being at very high risk of MACE, more than 10% of PAD patients who had revascularization surgery are hospitalized for major adverse limb events, including acute limb ischemia leading to amputation. Could combination therapy, an antithrombotic regimen comprised of a direct oral anticoagulant and an antiplatelet agent, help prevent limb ischemia and cardiovascular (CV) events in these high-risk patients?
Guest Authors: Navya Varshney, PharmD, BCPS and Rachel Lowe, PharmD, BCPS
Music by Good Talk
The Heart of the Matter – Is EMPA-REG a Game Changer for Diabetes Management?
Taking a CHANCE on Clopidogrel Plus Aspirin to Prevent Stroke Recurrence
How Long Is Long Enough? Extending OAC After Unprovoked PE
Managing Direct Oral Anticoagulants – What’s Our Role?
PCSK9 Inhibitors: Blockbusters or Bust?
Short-Course Dexamethasone for Asthma Exacerbations in Children
CVD Risk Scores - Are They Accurate?
Folic Acid: A Simple Answer to a Very Large Problem?
Dressed for Success? Professional Attire and Patient Perceptions
Insulin Delivery in Type 2 Diabetes: To Pump or Not to Pump?
Intensive Antiplatelet Therapy - Is Extended Therapy Worth It?
Co-trimoxazole+RAAS Inhibitors: A Deadly Combination?
Anticoagulation Bridge Therapy - Risks and Benefits Examined
Fish Oil for Rheumatoid Arthritis
Home-Based Primary Care: Can We Take These Results to the Bank?
Community Health Workers to Improve Asthma Outcomes
Potential Uses of Niacin: Flushing Out The Results of HPS2-THRIVE
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive